WHO ICTRP trial
Zoledronate early to patients after hip surgery -safe and effective?
EUCTR2020-000638-17-NO · EU Clinical Trials Register · Authorised
Key facts
| Trial ID | EUCTR2020-000638-17-NO |
|---|---|
| Public title | Zoledronate early to patients after hip surgery -safe and effective? |
| Scientific title | ZOLEDRONATE EARLY TO HIP FRACTURE PATIENTS – SAFE AND EFFECTIVE? A DOUBLE-BLINDED RANDOMIZED CONTROLLED TREATMENT STRATEGY TRIAL ON ZOLEDRONATE IN HIP FRACTURE PATIENTS THE ZEBRA TRIAL |
| Primary sponsor | Oslo University Hospital |
| Registry | EU Clinical Trials Register |
| Recruitment status | Authorised |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): yes |
| Countries | Norway |
| Conditions | Osteoporosis;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] |
| Interventions | Trade Name: Aclasta Product Name: Zoledronic Acid Product Code: M05B A08 Pharmaceutical Form: Infusion Pharmaceutical form of the placebo: Infusion Route of administration of the placebo: Intravenous use |
| Registration date | Apr 1, 2021 |
| Target size | 300 |
| Secondary IDs | 44107 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: